Latest News

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

Shares of MBX Biosciences, which is developing therapies that target endocrine and metabolic disorders, consisting of diabetes and weight problems, jumped nearly 44% in their Nasdaq debut on Friday.

The upbeat launching underscores investors' growing focus on weight-loss drugs after showing to be a reliable obesity treatment and showing possible to decrease stroke or heart attack risks.

The stock opened at $23 each, valuing the biotech company at about $694 million.

MBX stated on Thursday it had raised $163.2 million by selling 10.2 million shares at $16 each-- the high-end of its targeted series of $14 to $16 each-- in its going public.

The U.S. IPO market is on a route to healing, albeit uneven, after a two-year dry spell, on hopes of a possible rate cut by the Federal Reserve and lower market volatility.

MBX's success prosper for the IPO market that entered into a. traditional summer lull following the launching of freezer genuine. estate financial investment trust Lineage in July, the greatest. this year.

MBX's lead speculative prospect, MBX 2109, is being. developed to treat chronic hypoparathyroidism-- a condition in. which the body produces inadequate levels of parathyroid. hormone that interferes with calcium levels in the blood and bones.

The company is likewise establishing MBX 4291, an experimental. therapy for the treatment of weight problems. The therapy mimics the. effect of two gut hormones, GLP-1 and GIP.

Eli Lilly's tirzepatide, sold as Zepbound for weight. loss and Mounjaro for diabetes in the United States, likewise mimics. the function of these 2 gut hormones.

Wall Street estimates yearly worldwide sales of $150 billion. for weight-loss drugs by the early 2030s.

Separately, Bristol-Myers Squibb-backed Zenas BioPharma likewise. debuted on the Nasdaq, with its shares increasing almost 8%.

(source: Reuters)